Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer

Haruki Kaku, Takashi Saika, Tomoyasu Tsushima, Shin Ebara, Takashi Senoh, Toyoko Yamato, Yasutomo Nasu, Hiromi Kumon

    Research output: Contribution to journalArticlepeer-review

    59 Citations (Scopus)

    Abstract

    INTRODUCTION. In order to elucidate the influence of hormone-releasing hormone (LH-RH) agonist therapy cessation on pituitary/testicular function and its clinical implications, we investigated prospectively hormonal (luteinizing hormone: LH; testosterone: T) responses in patients with prostate cancer who received long-term LH-RH 10 agonist therapy. PATIENTS AND METHODS. A consecutive 32 patients who had received LH-RH agonist therapy over 24 months were enrolled. As a baseline, T and LH were measured at the time of LH-RH agonist therapy cessation, monthly for 3 months, and subsequently, every 3 months. RESULTS. The median duration of LH-RH agonist therapy was 30 months (24-87 months) with median follow-up duration of 24 months following cessation. All patients had castrated T levels and suppressed LH levels at baseline. Median duration of castrated T levels following cessation was 6 months. Median time to normalization of T levels was 24 months. LH levels returned to normal within 3 months in all cases. Patients who received androgen deprivation therapy for 30 months or longer required a longer time for recovery of T levels. Patients over 65 years of age showed a statistically significant longer time for recovery of T levels (P = 0.0167). CONCLUSIONS. Long-term LH-RH agonist therapy has remarkable effects on serum T level that last for a significant time after cessation, a fact that should be applied to the interpretation of both PSA and serum T levels after cessation of androgen deprivation therapy.

    Original languageEnglish
    Pages (from-to)439-444
    Number of pages6
    JournalProstate
    Volume66
    Issue number4
    DOIs
    Publication statusPublished - Mar 1 2006

    Keywords

    • Cessation of LH-RH
    • Luteinizing hormone
    • Prostate cancer
    • Testosterone

    ASJC Scopus subject areas

    • Oncology
    • Urology

    Fingerprint

    Dive into the research topics of 'Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer'. Together they form a unique fingerprint.

    Cite this